Initial decline in eGFR to predict tolvaptan response in autosomal-dominant polycystic kidney disease

Background Tolvaptan, a vasopressin V2 receptor antagonist, is used to treat autosomal-dominant polycystic kidney disease (ADPKD). Although tolvaptan curbs disease progression, a few reports have examined factors related to treatment response. The estimated glomerular filtration rate (eGFR) decrease...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical and experimental nephrology 2022-06, Vol.26 (6), p.540-551
Hauptverfasser:	Akihisa, Taro, Kataoka, Hiroshi, Makabe, Shiho, Manabe, Shun, Yoshida, Rie, Ushio, Yusuke, Sato, Masayo, Tsuchiya, Ken, Mochizuki, Toshio, Nitta, Kosaku
Format:	Artikel
Sprache:	eng
Schlagworte:	Epidermal growth factor receptors Glomerular filtration rate Kidney diseases Medicine Medicine & Public Health Nephrology Original Article Patients Polycystic kidney Prognosis Urology Vasopressin
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!